Target intelligence / Profile preview

Trauma memory reconsolidation through emotional processing

Molecular classification
Other
01

Overview

Trauma memory reconsolidation through emotional processing" refers to a neural and psychological process whereby previously consolidated traumatic memories are re-activated and, during a transient window, made susceptible to modification before being re-stabilized. Emotional processing refers to therapeutic or natural mechanisms that alter the affective (emotional) charge of traumatic memories during this reconsolidation window, potentially reducing their pathological impact—as in the treatment of PTSD. This is not a single molecule, receptor, or gene, but a complex process involving the amygdala, medial prefrontal cortex, hippocampus, and a cascade of neurochemical pathways (including stress hormones and changes in synaptic protein synthesis). Pharmacological (e.g., protein synthesis inhibitors in animal studies) and behavioral interventions (such as exposure therapies) can theoretically influence reconsolidation, but no single drug or receptor universally defines this target. Clinical and preclinical research aims to harness reconsolidation for therapeutic benefit by weakening or updating maladaptive emotional memories, though this is an area of ongoing investigation with important clinical and ethical considerations.

Other names
trauma memory reconsolidationemotional memory reconsolidationreconsolidation of traumatic memoryemotional processing of trauma memory
02

Mechanism of action

Disruption or alteration of memory reconsolidation (e.g., via pharmacological blockade of protein synthesis after memory retrieval) Facilitation of emotional processing through behavioral or therapeutic interventions that exploit reconsolidation windows

03

Biological functions

Emotional memory updatingMemory reconsolidationEmotional arousal modulationSynaptic plasticityStress response modulation
04

Disease associations

Neuropsychiatric disordersTrauma-related disorders (including PTSD)Emotional disorders
05

Safety considerations

Risk of destabilizing beneficial memoriesPotential for unintentional memory modificationUncertainty regarding long-term effects of pharmacological or behavioral intervention on memory
06

Interacting drugs

None directly (but certain drugs influence reconsolidation, e.g., protein synthesis inhibitors such as anisomycin in research contexts)
07

Biomarkers

None established; physiological or neuroimaging readouts (amygdala/prefrontal cortex activity, stress hormone levels) sometimes used in research

Beyond the preview

Go deeper on Trauma memory reconsolidation through emotional processing.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trauma memory reconsolidation through emotional processing.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call